Rare Subtype of Endometrial Cancer: Undifferentiated/Dedifferentiated Endometrial Carcinoma, from Genetic Aspects to Clinical Practice

Endometrial cancer (EC) is one of the most common gynecologic cancers worldwide. There were 417,367 newly diagnosed cases and 97,370 deaths due to this disease worldwide in 2020. The incidence rates have increased over time, especially in countries with rapid socioeconomic transitions, and EC has be...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 23; no. 7; p. 3794
Main Authors Tung, Hsiu-Jung, Wu, Ren-Chin, Lin, Chiao-Yun, Lai, Chyong-Huey
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 30.03.2022
MDPI
Subjects
Cancer therapies
Carcinoma - pathology
Carcinosarcoma - genetics
Carcinosarcoma - pathology
Case reports
Cell cycle
Chemotherapy
Clinical medicine
Clinical trials
Cystadenocarcinoma, Serous
dedifferentiated
Endometrial cancer
endometrial carcinoma
Endometrial Neoplasms - pathology
Endometrium
Epigenetics
Female
Gene expression
genetic expression
Growth patterns
Humans
Kinases
Ligands
Malignancy
Melanoma
molecular target
Mutation
Proteins
Review
Sarcoma
Sucrose
Taiwan
undifferentiated
Taiwan
United States > US
genetic expression
dedifferentiated
endometrial carcinoma
undifferentiated
molecular target
Online AccessGet full text

Cover

More Information
Summary:Endometrial cancer (EC) is one of the most common gynecologic cancers worldwide. There were 417,367 newly diagnosed cases and 97,370 deaths due to this disease worldwide in 2020. The incidence rates have increased over time, especially in countries with rapid socioeconomic transitions, and EC has been the most prevalent gynecologic malignancy in Taiwan since 2012. The new EC molecular classifications of The Cancer Genome Atlas (TCGA) Research Network include clear-cell carcinoma, serous carcinoma, and carcinosarcoma, while undifferentiated/dedifferentiated EC (UDEC) is not mentioned, and most previous clinical trials for EC have not included UDEC. UDEC is rare, has an aggressive growth pattern, tends to be diagnosed at an advanced stage, and is resistant to conventional chemotherapy. In this review, case series or case reports on the clinical features and genomic/epigenetic and expression profiles on UDEC data are summarized in order to identify potential molecular targets for current and future research.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms23073794